According to Marilyn Tavenner, president and CEO of America’s Health Insurance Plans, consumer and provider education plays a large role in the healthcare system’s transition to alternative payment-models and value-based care. Affordability is the operative word, for which Tavenner expects to be insurers biggest challenge in the coming future.
Consumer and provider education plays a large role in the healthcare system’s transition to alternative payment models and value-based care, explained Marilyn Tavenner, president and CEO of America’s Health Insurance Plans (AHIP). Affordability is the operative word, for which Tavenner expects to be insurers biggest challenge in the coming future.
Transcript (slightly modified):
What are the concerns AHIP’s members have voiced as the US healthcare system moves toward alternative payment-models and value-based care?
I think the biggest concerns are, our members are very enthusiastic about moving to this model and our members have much more experience with capitation, are paying for an episode of bundle of care, but providers do not have as much experience. So the concern is making sure that providers are educated, they have the technology they need, the consumers understand where we’re going and they’re on board.
So I think it’s really a big education process for consumers and for providers but it’s also making sure we move in a steady path and we don’t try to go there all at once and confuse people or have unintended consequences by moving too rapidly when people aren’t ready to go.
What do you think is the biggest challenge facing insurers in the next year?
Affordability, affordability, affordability. That’s going to be something you hear about. You’ll hear about it from Congress, you’ll hear about it from both presidential candidates, and you’ll hear about it from us. Pharma’s obviously a big piece of that but it’s not just pharma. It’s general services. How do we go about getting cost in line with what our economy and the public can handle? It’s a number 1 issue for consumers, understandably so.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More